Table 1:
Patient Characteristics at Initial Azathioprine Dose by rs2814778 Genotype in the VUMC Cohort
| CC (n=101) | TT or TC (n=1365) | Standardized Mean Difference | |
|---|---|---|---|
| EHR-reported race, n (%) | |||
| White | 5 (5.0) | 1296 (95.0) | −4.13 |
| Black | 96 (95.0) | 69 (5.0) | |
| Sex, n (%) | |||
| Female | 75 (74.3) | 910 (66.7) | −0.17 |
| Male | 26 (25.7) | 455 (33.3) | |
| Age in years, mean±SD | 39.8±15.5 | 44.4±17.5 | 0.28 |
| Indications, n (%) | |||
| Systemic lupus erythematosus (SLE) | 26 (25.7) | 139 (10.2) | −0.41 |
| Inflammatory bowel disease (IBD) | 57 (56.5) | 755 (55.3) | −0.02 |
| Inflammatory condition other than SLE or IBD | 18 (17.8) | 471 (34.5) | 0.39 |
| Initial daily dose (mg/day), median [IQR] | 50 [50–100] | 50 [50–100] | 0.15 |
| Calendar year of initial dose, median [IQR] | 2011 [2007–2013] | 2010 [2008–2013] | −0.01 |
| Tested prior to initiation of azathioprine, n (%) | 53 (52.5) | 696 (51.0) | −0.03 |
| Overall TPMT/NUDT15 metabolizer status, n (%) | |||
| Normal | 87 (86.1) | 1257 (92.1) | 0.19 |
| Indeterminate | 3 (3.0) | 5 (0.4) | −0.20 |
| Intermediate | 10 (9.9) | 100 (7.3) | −0.09 |
| Poor | 1 (1.0) | 3 (0.2) | −0.10 |
| Baseline WBC (K/μL), mean±SD | 7.5±3.5* | 8.8±3.7† | 0.34 |
EHR=electronic health record, TPMT=thiopurine S-methyltransferase, NUDT15=nudix hydrolase 15, WBC=white blood cell count
*
n=92
†
n=1215